Overview

GIP: Glucose-dependent Insulinotropic Peptide

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute on Aging (NIA)
Treatments:
Gastric Inhibitory Polypeptide